Trial Profile
Cimzia (Certolizumab Pegol) Pregnancy Exposure Registry: OTIS Autoimmune Diseases in Pregnancy Project
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease; Rheumatoid arthritis
- Focus Adverse reactions
- 01 Apr 2021 Planned number of patients changed from 500 to 925.
- 01 Apr 2021 Planned End Date changed from 1 Dec 2022 to 1 Oct 2026.
- 01 Apr 2021 Planned primary completion date changed from 1 Jan 2020 to 1 Sep 2023.